Remove 2029 Remove Insurance Remove Packaging
article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

Experts praise the reforms to rare disease and antimicrobial research, but they worry that some provisions in the EU Pharma Package may harm innovation on the continent, contrary to its stated objectives. In a bid to chase competitiveness, the EU is advancing its most drastic revision of pharmaceutical law in 20 years.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Other drugs are set to face competition too, with both MSD’s Keytruda (pembrolizumab) and Johnson & Johnson’s (J&J) Darzalex/Faspro (daratumumab and hyaluronidase-fihj) losing US exclusivity by 2029, representing a particular headwind in oncology. How will RFK Jr’s American dream for vaccines play out?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vor Bio back from brink with autoimmune drug deal rising to $4bn

Pharmaceutical Technology

For example, the rheumatoid arthritis drug market across the eight major global markets is forecast to reach $29.1bn by 2029, according to analysis by GlobalData. Sanofi’s blockbuster autoimmune drug Dupixent (dupilumab) is one of the best-selling drugs in the world, representing the lucrative nature of the sector.

article thumbnail

AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

Pharmaceutical Technology

According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an “attractive opportunity” for long-term investors. Give your business an edge with our leading industry insights.

article thumbnail

Vetter breaks ground on $285m US clinical manufacturing site

Pharmaceutical Technology

Reports Contract Injectable Packaging Trends in the Bio/Pharma Industry Data Insights The gold standard of business intelligence. The facility will be complete and ready for media fill by late 2029, with plans to move Vetter’s existing clinical operations in Skokie. Find out more Sign up for our daily news round-up!

article thumbnail

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

A report by UNAIDS predicts that six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if US-supported HIV treatment and prevention services collapse. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

article thumbnail

EHDS regulation will depend on strong patient confidence

Pharmaceutical Technology

The regulation came into force in March 2025; however, it has not yet come into application, with this set to happen in March 2029. The European Commission (EC) faces a March 2027 deadline to adopt several key implementing acts, which will lay out detailed rules for putting the regulation into practice.